JP2010517538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010517538A5 JP2010517538A5 JP2009548481A JP2009548481A JP2010517538A5 JP 2010517538 A5 JP2010517538 A5 JP 2010517538A5 JP 2009548481 A JP2009548481 A JP 2009548481A JP 2009548481 A JP2009548481 A JP 2009548481A JP 2010517538 A5 JP2010517538 A5 JP 2010517538A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- dcir
- immunoglobulin
- pharmaceutical composition
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 claims 11
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 claims 11
- 108060003951 Immunoglobulin Proteins 0.000 claims 11
- 102000018358 immunoglobulin Human genes 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 6
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims 4
- -1 IL14 Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108010067331 coherin Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 108010066676 Abrin Proteins 0.000 claims 1
- 229930195730 Aflatoxin Natural products 0.000 claims 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 108030001720 Bontoxilysin Proteins 0.000 claims 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 101150093802 CXCL1 gene Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- 101001043796 Gallus gallus Interleukin-8 Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 claims 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 102000026633 IL6 Human genes 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003815 Interleukin-11 Human genes 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 101800003050 Interleukin-16 Proteins 0.000 claims 1
- 102000049772 Interleukin-16 Human genes 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 102100039897 Interleukin-5 Human genes 0.000 claims 1
- 102100021592 Interleukin-7 Human genes 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 231100000678 Mycotoxin Toxicity 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 108010079723 Shiga Toxin Proteins 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000005409 aflatoxin Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 108010045512 cohesins Proteins 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 102000055414 human LTB Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 102000049853 macrophage stimulating protein Human genes 0.000 claims 1
- 108010053292 macrophage stimulating protein Proteins 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000002297 mitogenic effect Effects 0.000 claims 1
- 239000002636 mycotoxin Substances 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims 1
- 239000003998 snake venom Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 239000002708 spider venom Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims 1
- 229950010357 tetrodotoxin Drugs 0.000 claims 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88803207P | 2007-02-02 | 2007-02-02 | |
| US60/888,032 | 2007-02-02 | ||
| PCT/US2008/052850 WO2008097866A2 (en) | 2007-02-02 | 2008-02-01 | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010517538A JP2010517538A (ja) | 2010-05-27 |
| JP2010517538A5 true JP2010517538A5 (https=) | 2011-03-17 |
| JP5377330B2 JP5377330B2 (ja) | 2013-12-25 |
Family
ID=39682352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548481A Expired - Fee Related JP5377330B2 (ja) | 2007-02-02 | 2008-02-01 | 抗原提示細胞上に発現されたｄｃｉｒへの抗原のターゲティングに基づくワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8057798B2 (https=) |
| EP (2) | EP2115002B1 (https=) |
| JP (1) | JP5377330B2 (https=) |
| KR (1) | KR20090114430A (https=) |
| CN (1) | CN101679508B (https=) |
| AU (1) | AU2008214032B2 (https=) |
| BR (1) | BRPI0807160A2 (https=) |
| CA (1) | CA2715044A1 (https=) |
| IL (1) | IL200088A0 (https=) |
| MX (1) | MX2009008140A (https=) |
| NZ (2) | NZ578696A (https=) |
| TW (1) | TWI446921B (https=) |
| WO (1) | WO2008097866A2 (https=) |
| ZA (1) | ZA200905347B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| KR20090114430A (ko) * | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| US7786267B2 (en) * | 2007-02-02 | 2010-08-31 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| CA2633246A1 (en) | 2008-06-19 | 2009-12-19 | Universite Laval | Identification of therapeutic agents for hiv infection |
| AU2010222928B2 (en) | 2008-07-16 | 2012-11-29 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
| WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
| DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
| EP2406289B1 (en) | 2009-03-10 | 2017-02-22 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| FR2955773B1 (fr) | 2010-02-01 | 2017-05-26 | Commissariat Energie Atomique | Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination |
| JP5641508B2 (ja) * | 2010-02-23 | 2014-12-17 | 国立大学法人 東京大学 | 樹状細胞免疫受容体刺激剤 |
| MX2012012833A (es) * | 2010-05-07 | 2012-11-30 | Baylor Res Inst | Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir). |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| BR112013002940A2 (pt) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos |
| US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ｎｇｆ組成物およびその使用 |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| CA2831294A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
| TW201247700A (en) * | 2011-05-05 | 2012-12-01 | Baylor Res Inst | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists |
| KR102274211B1 (ko) * | 2011-11-23 | 2021-07-09 | 인3바이오 리미티드 | 재조합 단백질 및 그들의 치료적 용도 |
| CN104769104A (zh) * | 2011-12-12 | 2015-07-08 | 细胞药物有限公司 | 扩大t细胞的方法 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CN103045627B (zh) * | 2012-11-09 | 2015-04-15 | 逢甲大学 | 于细胞内制造蛋白复合物的方法 |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| CA2916694C (en) | 2013-06-28 | 2023-01-17 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| JP7037884B2 (ja) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| KR102717969B1 (ko) | 2014-02-21 | 2024-10-15 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| TWI731535B (zh) | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| US11000597B2 (en) | 2015-01-21 | 2021-05-11 | University Of Florida Research Foundation, Incorporated | Engineered receptor/ligand system for delivery of therapeutic agents |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| WO2017201635A1 (zh) * | 2016-05-23 | 2017-11-30 | 蔡胜和 | 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用 |
| BR112018075630A2 (pt) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de fármaco de anticorpo |
| EP3458479B1 (en) | 2016-06-08 | 2020-11-04 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート |
| EP3469000A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| AU2018224044B2 (en) | 2017-02-21 | 2024-01-25 | The Uab Research Foundation | Modified AAV capsid proteins and uses thereof |
| WO2018195302A1 (en) | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| CN117004573A (zh) * | 2017-12-13 | 2023-11-07 | 苏州康聚生物科技有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| WO2019183093A1 (en) * | 2018-03-19 | 2019-09-26 | Abeome Corporation | High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| CN114423793A (zh) | 2019-09-18 | 2022-04-29 | 分子模板公司 | 包含志贺菌毒素a亚基支架的pd-l1结合分子 |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CA3209251A1 (en) * | 2021-01-29 | 2022-08-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3949064A (en) * | 1973-10-26 | 1976-04-06 | Baxter Laboratories, Inc. | Method of detecting antigens or antibodies |
| US4174384A (en) * | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| DE69434931T2 (de) * | 1993-04-02 | 2007-11-22 | Rigel Pharmaceuticals, Inc., South San Francisco | Methode zur selektiven inaktivierung der viralen replication |
| WO1997034634A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
| AR014891A1 (es) * | 1997-07-09 | 2001-04-11 | Schering Corp | Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados |
| US20020025315A1 (en) * | 1998-01-14 | 2002-02-28 | Naveen N. Anand | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| US20050106700A1 (en) * | 2001-10-11 | 2005-05-19 | Tsuyoshi Nomura | Method of purifying recombinant fused protein and method of producing protein using the same |
| WO2003046012A1 (en) * | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20070224205A1 (en) * | 2006-03-07 | 2007-09-27 | Powell Thomas J | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| US7786267B2 (en) * | 2007-02-02 | 2010-08-31 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| KR20090114430A (ko) | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
| NZ599777A (en) * | 2007-11-07 | 2013-09-27 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
-
2008
- 2008-02-01 KR KR1020097018301A patent/KR20090114430A/ko not_active Ceased
- 2008-02-01 EP EP08728868.4A patent/EP2115002B1/en active Active
- 2008-02-01 WO PCT/US2008/052850 patent/WO2008097866A2/en not_active Ceased
- 2008-02-01 CN CN200880011285.1A patent/CN101679508B/zh not_active Expired - Fee Related
- 2008-02-01 EP EP12164572A patent/EP2527363A1/en not_active Withdrawn
- 2008-02-01 NZ NZ578696A patent/NZ578696A/en not_active IP Right Cessation
- 2008-02-01 CA CA2715044A patent/CA2715044A1/en not_active Abandoned
- 2008-02-01 BR BRPI0807160A patent/BRPI0807160A2/pt not_active IP Right Cessation
- 2008-02-01 NZ NZ593450A patent/NZ593450A/xx not_active IP Right Cessation
- 2008-02-01 MX MX2009008140A patent/MX2009008140A/es active IP Right Grant
- 2008-02-01 JP JP2009548481A patent/JP5377330B2/ja not_active Expired - Fee Related
- 2008-02-01 US US12/024,897 patent/US8057798B2/en active Active
- 2008-02-01 TW TW097104113A patent/TWI446921B/zh not_active IP Right Cessation
- 2008-02-01 AU AU2008214032A patent/AU2008214032B2/en not_active Ceased
-
2009
- 2009-07-27 IL IL200088A patent/IL200088A0/en unknown
- 2009-07-30 ZA ZA200905347A patent/ZA200905347B/xx unknown
-
2011
- 2011-09-16 US US13/234,914 patent/US8449888B2/en not_active Expired - Fee Related
-
2012
- 2012-04-24 US US13/454,404 patent/US8586052B2/en active Active
-
2013
- 2013-04-29 US US13/872,793 patent/US9102730B2/en active Active
- 2013-10-03 US US14/045,454 patent/US9234040B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010517538A5 (https=) | ||
| Chen et al. | Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis | |
| JP2010518020A5 (https=) | ||
| CN1072505C (zh) | 生物应答修饰因子的新颖抗体传递系统 | |
| CA2138928C (en) | Immunoconjugates | |
| Banga | Therapeutic peptides and proteins: formulation, processing, and delivery systems | |
| US7960145B2 (en) | Compositions and methods for generating antibodies | |
| US7582288B2 (en) | Methods of targeting multiple cytokines | |
| TWI422594B (zh) | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 | |
| Thom et al. | Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system | |
| JP2010518024A5 (https=) | ||
| Patel et al. | Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities | |
| JP2008543278A5 (https=) | ||
| EP2760886A1 (en) | Immunocytokine combination therapy | |
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| IL298121A (en) | cd40 binding protein | |
| Zhang et al. | Enhancement of immunity to an Escherichia coli vaccine in mice orally inoculated with a fusion gene encoding porcine interleukin 4 and 6 | |
| EP2091972B1 (en) | Multi-modal cancer therapy using viral hitch-hiking | |
| Huang et al. | Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40 (+) cells | |
| Schmid et al. | Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads | |
| Xiang | Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins | |
| Vallera et al. | Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model | |
| CN116473938B (zh) | 一种血液肿瘤靶向外泌体递送载体及其应用 | |
| Chi et al. | APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin | |
| US20040120935A1 (en) | Genetically modified yt cell line and use thereof |